Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Недетская болезнь: сложности, с которыми сталкиваются люди с атопическим дерматитом
Недетская болезнь: сложности, с которыми сталкиваются люди с атопическим дерматитом
Недетская болезнь: сложности, с которыми сталкиваются люди с атопическим дерматитом. Дерматология (Прил. к журн. Consilium Medicum). 2019; 3: 37.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Weidinger S, Beck LA, Bieber T et al. Atopic dermatitis. Nat Rev Dis Primers 2018; 4 (1): 1. DOI: 10.1038/s41572-018-0001-z
2. Simpson E, Bieber T, Eckert L. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b on clinical trial of dupilumab in adults. Am Acad Dermatol 2016; 74 (3): 491–8.
3. Zuberbier T, Orlow S, Paller A. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118 (1): 226–32.
4. Vangipuram R, Tyring SK. Dupilumab for Moderate-to-Severe Atopic Dermatitis. Skin Therapy Letter 2017; 22 (6): 1–4.
5. Silverberg J. Public Health Burden and Epidemiology of Atopic Dermatitis. Dermatol Clinics 2017; 35 (3): 283–9.
6. Thomsen SF. Atopic Dermatitis: Natural History, Diagnosis, and Treatment 2014. ISRN Allergy 2014; p. 1–7.
7. Ehlers A, Ulrich S, Uwe G. Treatment of Atopic Dermatitis: A Comparison of Psychological and Dermatological Approaches to Relapse Prevention. J Consult Clin Psychol 1995; 63 (4): 624–35.
8. Simpson E, Bieber T, Guttman-Yassky E. Two Phase 3 trials of Dupilumab vs. Placebo in Atopic Dermatitis. New Engl J Med 2016, 375 (24): 2335–48.
9. Ashcroft D, Dimmock P, Garside R. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ 2005; 330 (7490): 516–22.
10. Wei W, Anderson P, Gadkari A et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol 2018; 45 (2): 150–7. DOI: 10.1111/1346-8138.14116
11. Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S et al. Sleep disturbances in children with atopic dermatitis. Arch Pediatr Adolesc Med 1995; 149: 856–60.
12. Romanos M, Gerlach M, Warnke A, Schmitt J. Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. J Epidemiol Community Health 2010; 64: 269–73.
13. Silverberg JI. Health Care Utilization, Patient Costs, and Access to Care in US Adults with Eczema: A Population-Based Study. JAMA Dermatol 2015. https://doi.org/10.1001/jamadermatol.2014.5432
14. Torrelo A, Ortiz J, Alomar A. Atopic dermatitis: impact on quality of life and patients’ attitudes toward its management. Eur J Dermatol 2012; 22 (4): 97–105.
15. Holm E, Esmann S, Jemec G. The handicap caused by atopic dermatitis – sick leave and job avoidance. J Eur Acad Dermatol Venereol 2006; 20 (3): 255–9.
16. Schmid-Ott G, Jaeger B, Adamek C et al. Levels of circulating CD8 T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. J Allergy Clin Immunol 2001; 107: 171–7.
17. National Eczema Foundation. https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis
18. Rajani K, Schlichte M. Diet and Dermatitis: Food Triggers. J Clin Aesthetic Dermatol 2014; 7 (3): 30–6.
19. Campana R, Dzoro S, Mittermann I et al. Molecular Aspects of Allergens in Atopic Dermatitis. Curr Opin Allergy Clin Immunol 2017; 17 (4): 269–77.
20. Pónyai G, Hidvégi B, Németh I et al. Contact and Aeroallergens in Adulthood Atopic Dermatitis. J Eur Acad Dermatol Venereol 2008; 22 (11): 1346–55.
2. Simpson E, Bieber T, Eckert L. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b on clinical trial of dupilumab in adults. Am Acad Dermatol 2016; 74 (3): 491–8.
3. Zuberbier T, Orlow S, Paller A. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118 (1): 226–32.
4. Vangipuram R, Tyring SK. Dupilumab for Moderate-to-Severe Atopic Dermatitis. Skin Therapy Letter 2017; 22 (6): 1–4.
5. Silverberg J. Public Health Burden and Epidemiology of Atopic Dermatitis. Dermatol Clinics 2017; 35 (3): 283–9.
6. Thomsen SF. Atopic Dermatitis: Natural History, Diagnosis, and Treatment 2014. ISRN Allergy 2014; p. 1–7.
7. Ehlers A, Ulrich S, Uwe G. Treatment of Atopic Dermatitis: A Comparison of Psychological and Dermatological Approaches to Relapse Prevention. J Consult Clin Psychol 1995; 63 (4): 624–35.
8. Simpson E, Bieber T, Guttman-Yassky E. Two Phase 3 trials of Dupilumab vs. Placebo in Atopic Dermatitis. New Engl J Med 2016, 375 (24): 2335–48.
9. Ashcroft D, Dimmock P, Garside R. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ 2005; 330 (7490): 516–22.
10. Wei W, Anderson P, Gadkari A et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol 2018; 45 (2): 150–7. DOI: 10.1111/1346-8138.14116
11. Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S et al. Sleep disturbances in children with atopic dermatitis. Arch Pediatr Adolesc Med 1995; 149: 856–60.
12. Romanos M, Gerlach M, Warnke A, Schmitt J. Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. J Epidemiol Community Health 2010; 64: 269–73.
13. Silverberg JI. Health Care Utilization, Patient Costs, and Access to Care in US Adults with Eczema: A Population-Based Study. JAMA Dermatol 2015. https://doi.org/10.1001/jamadermatol.2014.5432
14. Torrelo A, Ortiz J, Alomar A. Atopic dermatitis: impact on quality of life and patients’ attitudes toward its management. Eur J Dermatol 2012; 22 (4): 97–105.
15. Holm E, Esmann S, Jemec G. The handicap caused by atopic dermatitis – sick leave and job avoidance. J Eur Acad Dermatol Venereol 2006; 20 (3): 255–9.
16. Schmid-Ott G, Jaeger B, Adamek C et al. Levels of circulating CD8 T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. J Allergy Clin Immunol 2001; 107: 171–7.
17. National Eczema Foundation. https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis
18. Rajani K, Schlichte M. Diet and Dermatitis: Food Triggers. J Clin Aesthetic Dermatol 2014; 7 (3): 30–6.
19. Campana R, Dzoro S, Mittermann I et al. Molecular Aspects of Allergens in Atopic Dermatitis. Curr Opin Allergy Clin Immunol 2017; 17 (4): 269–77.
20. Pónyai G, Hidvégi B, Németh I et al. Contact and Aeroallergens in Adulthood Atopic Dermatitis. J Eur Acad Dermatol Venereol 2008; 22 (11): 1346–55.
2. Simpson E, Bieber T, Eckert L. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b on clinical trial of dupilumab in adults. Am Acad Dermatol 2016; 74 (3): 491–8.
3. Zuberbier T, Orlow S, Paller A. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118 (1): 226–32.
4. Vangipuram R, Tyring SK. Dupilumab for Moderate-to-Severe Atopic Dermatitis. Skin Therapy Letter 2017; 22 (6): 1–4.
5. Silverberg J. Public Health Burden and Epidemiology of Atopic Dermatitis. Dermatol Clinics 2017; 35 (3): 283–9.
6. Thomsen SF. Atopic Dermatitis: Natural History, Diagnosis, and Treatment 2014. ISRN Allergy 2014; p. 1–7.
7. Ehlers A, Ulrich S, Uwe G. Treatment of Atopic Dermatitis: A Comparison of Psychological and Dermatological Approaches to Relapse Prevention. J Consult Clin Psychol 1995; 63 (4): 624–35.
8. Simpson E, Bieber T, Guttman-Yassky E. Two Phase 3 trials of Dupilumab vs. Placebo in Atopic Dermatitis. New Engl J Med 2016, 375 (24): 2335–48.
9. Ashcroft D, Dimmock P, Garside R. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ 2005; 330 (7490): 516–22.
10. Wei W, Anderson P, Gadkari A et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol 2018; 45 (2): 150–7. DOI: 10.1111/1346-8138.14116
11. Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S et al. Sleep disturbances in children with atopic dermatitis. Arch Pediatr Adolesc Med 1995; 149: 856–60.
12. Romanos M, Gerlach M, Warnke A, Schmitt J. Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. J Epidemiol Community Health 2010; 64: 269–73.
13. Silverberg JI. Health Care Utilization, Patient Costs, and Access to Care in US Adults with Eczema: A Population-Based Study. JAMA Dermatol 2015. https://doi.org/10.1001/jamadermatol.2014.5432
14. Torrelo A, Ortiz J, Alomar A. Atopic dermatitis: impact on quality of life and patients’ attitudes toward its management. Eur J Dermatol 2012; 22 (4): 97–105.
15. Holm E, Esmann S, Jemec G. The handicap caused by atopic dermatitis – sick leave and job avoidance. J Eur Acad Dermatol Venereol 2006; 20 (3): 255–9.
16. Schmid-Ott G, Jaeger B, Adamek C et al. Levels of circulating CD8 T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. J Allergy Clin Immunol 2001; 107: 171–7.
17. National Eczema Foundation. https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis
18. Rajani K, Schlichte M. Diet and Dermatitis: Food Triggers. J Clin Aesthetic Dermatol 2014; 7 (3): 30–6.
19. Campana R, Dzoro S, Mittermann I et al. Molecular Aspects of Allergens in Atopic Dermatitis. Curr Opin Allergy Clin Immunol 2017; 17 (4): 269–77.
20. Pónyai G, Hidvégi B, Németh I et al. Contact and Aeroallergens in Adulthood Atopic Dermatitis. J Eur Acad Dermatol Venereol 2008; 22 (11): 1346–55.
________________________________________________
2. Simpson E, Bieber T, Eckert L. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b on clinical trial of dupilumab in adults. Am Acad Dermatol 2016; 74 (3): 491–8.
3. Zuberbier T, Orlow S, Paller A. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118 (1): 226–32.
4. Vangipuram R, Tyring SK. Dupilumab for Moderate-to-Severe Atopic Dermatitis. Skin Therapy Letter 2017; 22 (6): 1–4.
5. Silverberg J. Public Health Burden and Epidemiology of Atopic Dermatitis. Dermatol Clinics 2017; 35 (3): 283–9.
6. Thomsen SF. Atopic Dermatitis: Natural History, Diagnosis, and Treatment 2014. ISRN Allergy 2014; p. 1–7.
7. Ehlers A, Ulrich S, Uwe G. Treatment of Atopic Dermatitis: A Comparison of Psychological and Dermatological Approaches to Relapse Prevention. J Consult Clin Psychol 1995; 63 (4): 624–35.
8. Simpson E, Bieber T, Guttman-Yassky E. Two Phase 3 trials of Dupilumab vs. Placebo in Atopic Dermatitis. New Engl J Med 2016, 375 (24): 2335–48.
9. Ashcroft D, Dimmock P, Garside R. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ 2005; 330 (7490): 516–22.
10. Wei W, Anderson P, Gadkari A et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol 2018; 45 (2): 150–7. DOI: 10.1111/1346-8138.14116
11. Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S et al. Sleep disturbances in children with atopic dermatitis. Arch Pediatr Adolesc Med 1995; 149: 856–60.
12. Romanos M, Gerlach M, Warnke A, Schmitt J. Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. J Epidemiol Community Health 2010; 64: 269–73.
13. Silverberg JI. Health Care Utilization, Patient Costs, and Access to Care in US Adults with Eczema: A Population-Based Study. JAMA Dermatol 2015. https://doi.org/10.1001/jamadermatol.2014.5432
14. Torrelo A, Ortiz J, Alomar A. Atopic dermatitis: impact on quality of life and patients’ attitudes toward its management. Eur J Dermatol 2012; 22 (4): 97–105.
15. Holm E, Esmann S, Jemec G. The handicap caused by atopic dermatitis – sick leave and job avoidance. J Eur Acad Dermatol Venereol 2006; 20 (3): 255–9.
16. Schmid-Ott G, Jaeger B, Adamek C et al. Levels of circulating CD8 T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. J Allergy Clin Immunol 2001; 107: 171–7.
17. National Eczema Foundation. https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis
18. Rajani K, Schlichte M. Diet and Dermatitis: Food Triggers. J Clin Aesthetic Dermatol 2014; 7 (3): 30–6.
19. Campana R, Dzoro S, Mittermann I et al. Molecular Aspects of Allergens in Atopic Dermatitis. Curr Opin Allergy Clin Immunol 2017; 17 (4): 269–77.
20. Pónyai G, Hidvégi B, Németh I et al. Contact and Aeroallergens in Adulthood Atopic Dermatitis. J Eur Acad Dermatol Venereol 2008; 22 (11): 1346–55.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.